Bernard Pietenpol

Susan G. Komen® Names Dr. Ann H. Partridge as New Chief Scientific Advisor

Retrieved on: 
Wednesday, December 7, 2022
Vanderbilt University Medical Center, Dana–Farber Cancer Institute, Oncology, Breast cancer, Harvard University, Research, Health, Patient, Bernard Pietenpol, Cancer, Eric, Disease, Susan G. Komen for the Cure, Medicine, MPH, Woman, Strathcona County, Quality of life, United States Air Force Scientific Advisory Board, Dietary supplement, Management, MD

DALLAS, Dec. 7, 2022 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced Ann H. Partridge, MD, MPH, as Chief Scientific Advisor, where she will help identify the greatest needs and opportunities to invest in breast cancer research and guide Komen's research strategy, investment, and programs. In her role, she will co-lead an executive committee of eight distinguished breast cancer researchers, clinicians and patient advocates who make up Komen's Scientific Advisory Board.

Key Points: 
  • Ann H. Partridge, MD, MPH, has been named Chief Scientific Advisor for Susan G. Komen.
  • "Susan G. Komen is honored to have Dr. Partridge serve as Komen's new Chief Scientific Advisor.
  • Partridge replaces George Sledge, Jr., MD, who served as Chief Scientific Advisor for 10 years, and will serve alongsideJennifer Pietenpol, Ph.D. Pietenpol is the Chief Scientific and Strategy Officer at Vanderbilt University Medical Center.
  • This is the first time Komen has had two women serving simultaneously in the Chief Scientific Advisor roles.

SUSAN G. KOMEN® INVESTS $21.7 MILLION IN RESEARCH FOCUSED ON IMPROVING OUTCOMES FOR BREAST CANCER PATIENTS

Retrieved on: 
Wednesday, June 22, 2022
Vanderbilt University Medical Center, Government, Biology, Disease, Patient, Research, Breast, Bernard Pietenpol, Metastasis, Susan, Recurrence, Mission, Benjamin, SVP, Breast cancer, Pharmaceutical industry, Dietary supplement, Medical imaging, Birth control

With this investment, Komen is now supporting more than 152 active research projects representing more than $115 million in funding.

Key Points: 
  • With this investment, Komen is now supporting more than 152 active research projects representing more than $115 million in funding.
  • "With this investment, we're supporting some of the top breast cancer researchers who share our mission and giving everyone impacted by breast cancer hope, as we move closer to the cures for breast cancers."
  • Of the total $21.7 million awarded today:
    79 percent supports research focused on the most aggressive breast cancers, metastasis and recurrence;
    33 percent supports clinical trials;
    20 percent supports research focused on eliminating breast cancer disparities;
    "We still have much to learn about aggressive breast cancers and breast cancers that recur and metastasize.
  • Susan G. Komenis the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever.